Redmile Group LLC decreased its position in shares of Chimerix, Inc. (NASDAQ:CMRX) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,207,575 shares of the biopharmaceutical company’s stock after selling 117,480 shares during the period. Chimerix comprises 1.4% of Redmile Group LLC’s holdings, making the stock its 28th largest holding. Redmile Group LLC owned approximately 8.94% of Chimerix worth $22,931,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of CMRX. Dimensional Fund Advisors LP boosted its position in shares of Chimerix by 114.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock worth $6,656,000 after acquiring an additional 557,927 shares in the last quarter. Morgan Stanley boosted its position in shares of Chimerix by 203.9% during the 1st quarter. Morgan Stanley now owns 618,074 shares of the biopharmaceutical company’s stock worth $3,944,000 after acquiring an additional 414,717 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Chimerix during the 1st quarter worth approximately $1,975,000. Vanguard Group Inc. boosted its position in shares of Chimerix by 13.1% during the 1st quarter. Vanguard Group Inc. now owns 1,848,257 shares of the biopharmaceutical company’s stock worth $11,792,000 after acquiring an additional 213,894 shares in the last quarter. Finally, AXA boosted its position in shares of Chimerix by 284.9% during the 2nd quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock worth $1,409,000 after acquiring an additional 191,400 shares in the last quarter. Institutional investors and hedge funds own 67.53% of the company’s stock.
Several analysts recently issued reports on CMRX shares. ValuEngine lowered shares of Chimerix from a “sell” rating to a “strong sell” rating in a research report on Monday, September 18th. Zacks Investment Research lowered shares of Chimerix from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th.
TRADEMARK VIOLATION WARNING: “Redmile Group LLC Has $22.93 Million Position in Chimerix, Inc. (CMRX)” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://transcriptdaily.com/2017/10/08/redmile-group-llc-has-22-93-million-position-in-chimerix-inc-cmrx.html.
Chimerix, Inc. (NASDAQ:CMRX) traded down 1.89% during mid-day trading on Friday, hitting $5.19. 593,283 shares of the company traded hands. Chimerix, Inc. has a one year low of $3.66 and a one year high of $6.64. The firm’s market capitalization is $244.17 million. The firm has a 50 day moving average of $4.91 and a 200 day moving average of $5.18.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.05. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%. The business had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $1.28 million. Equities research analysts expect that Chimerix, Inc. will post ($1.63) earnings per share for the current fiscal year.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.